Cargando…

Ferroptosis vulnerability in MYCN‐driven neuroblastomas

Detalles Bibliográficos
Autores principales:	Dasgupta, Shayani, Gan, Boyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339235/ https://www.ncbi.nlm.nih.gov/pubmed/35908258 http://dx.doi.org/10.1002/ctm2.963

Ejemplares similares

MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma
por: Lu, Yuxiong, et al.
Publicado: (2021)

MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma
por: Tao, Ling, et al.
Publicado: (2022)

MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis
por: Alborzinia, Hamed, et al.
Publicado: (2022)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

How erastin assassinates cells by ferroptosis revealed
por: Gan, Boyi
Publicado: (2022)

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014)

Ferroptosis as an important driver of lupus
por: Mao, Chao, et al.
Publicado: (2021)

MYCN-enhanced Oxidative and Glycolytic Metabolism Reveals Vulnerabilities for Targeting Neuroblastoma
por: Oliynyk, Ganna, et al.
Publicado: (2019)

Serine–glycine-one-carbon metabolism: vulnerabilities in MYCN-amplified neuroblastoma
por: Zhao, Erhu, et al.
Publicado: (2020)

Penetrating enemy territory: Soluble PCNA-peptides stress out MYCN-overexpressing neuroblastomas
por: Bielinsky, Anja-Katrin
Publicado: (2015)

Cytochrome P450 reductase (POR) as a ferroptosis fuel
por: Koppula, Pranavi, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma
por: Alborzinia, Hamed, et al.
Publicado: (2023)

Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma
por: Bogen, Dominik, et al.
Publicado: (2015)

Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma
por: Zhai, Lei, et al.
Publicado: (2023)

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023)

A Chemo-Genomic Approach Identifies Diverse Epigenetic Therapeutic Vulnerabilities in MYCN-Amplified Neuroblastoma
por: Krstic, Aleksandar, et al.
Publicado: (2021)

Ferroptosis: the vulnerability within a cancer monster
por: Xie, Wanqing, et al.
Publicado: (2023)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
por: Borenäs, Marcus, et al.
Publicado: (2021)

NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers
por: Takatori, Atsushi, et al.
Publicado: (2021)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

Regulation of MYCN expression in human neuroblastoma cells
por: Jacobs, Joannes FM, et al.
Publicado: (2009)

MYCN and mutationally activated ALK synergise in neuroblastoma
Publicado: (2012)

MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020)

MYCN in Neuroblastoma: “Old Wine into New Wineskins”
por: Braoudaki, Maria, et al.
Publicado: (2021)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies
por: Althoff, K, et al.
Publicado: (2015)

The pre-rRNA processing factor DEF is rate limiting for the pathogenesis of MYCN-driven neuroblastoma
por: Tao, T, et al.
Publicado: (2017)

A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma
por: Cheung, Belamy B., et al.
Publicado: (2021)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma
por: Lee, Eunjin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n83aumlajfkm1g5alqlddkjplm